Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;73(1):65-70.
doi: 10.1007/s12020-021-02718-w. Epub 2021 Apr 15.

Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review

Adnan Zaina  1   2 , Yuval Grober  3 , Ali Abid  4 , Eldad Arad  4 , Elena Golden  4 , Samih Badarny  5
Affiliations
Review

Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review

Adnan Zaina et al. Endocrine. 2021 Jul.

Abstract

Purpose: Diabetes mellitus (DM) represents one of the most frequent comorbidities in patients with acromegaly. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent an important class for diabetes management. However, limited data is reported regarding the use of this class in patients with acromegaly and diabetes.

Methods: Reporting data regarding patients with acromegaly and diabetes under treatment with SGLT2i.

Results: 29 acromegalic patients with diabetes were identified. Treatment with SGLT-2i was documented in nine patients, out of them 5 females and 4 males with a mean age (SD) of 61 ± 12 yr. The mean (SD) duration of treatment with SGLT2i was 27.5 ± 7.3 months. Mean HbA1c before and after SGLT-2i initiation was 8.1 ± 1.1 and 7.0 ± 0.9% respectively. Mean IGF-1 level (SD) before SGLT-2i initiation was 177 ± 68 ng/mL and the mean GH level (SD) was 0.7 ± 0.5 µg/L. All nine patients are still under treatment with SGLT2i and none of them had reported any adverse reaction related to SGLT2i.

Conclusions: The present article provides us for the first time with new data regarding the use of SGLT2i among acromegalic patients with diabetes.

Keywords: Acromegaly; Diabetes; Diabetic ketoacidosis; SGLT2i.

PubMed Disclaimer

References

    1. L. Katznelson, E.R. Laws, S. Melmed et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014) - DOI
    1. M.R. Gadelha, L. Kasuki, D.S.T. Lim, M. Fleseriu, Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr. Rev. 40, 268–332 (2019) - DOI
    1. B. Zinman, C. Wanner, J.M. Lachin,EMPA-REG OUTCOME Investigators et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015) - DOI
    1. J.J.V. McMurray, D.L. DeMets, S.E. Inzucchi, L. Køber, M.N. Kosiborod, A.M. Langkilde, F.A. Martinez, O. Bengtsson, P. Ponikowski, M.S. Sabatine, M. Sjöstrand, S.D. Solomon,DAPA-HF Committees and Investigators, A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur. J. Heart Fail. 21, 665–675 (2019) - DOI
    1. C. Wanner, H.J.L. Heerspink, B. Zinman, S.E. Inzucchi, A. Koitka-Weber, M. Mattheus, S. Hantel, H.J. Woerle, U.C. Broedl, M. von Eynatten, P.H. Groop,EMPA-REG OUTCOME Investigators, Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J. Am. Soc. Nephrol. 29, 2755–2769 (2018) - DOI

MeSH terms

Substances

LinkOut - more resources